title: Statins and myocardial infarction: Type, dose, and administration time: Does it matter?
abstract: Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration.
authors.affiliation: Department of Cardiology, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papageorgiou
authors.affiliation: 1st Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece.
authors.forename: Effimia
authors.initials: E
authors.lastname: Zacharia
authors.affiliation: Department of Cardiology, Detroit Medical Center, Wayne State University, Detroit, MI. Electronic address: alexbriasoulis@gmail.com.
authors.forename: Alexandros
authors.initials: A
authors.lastname: Briasoulis
authors.affiliation: Department of Cardiology, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Androulakis
authors.affiliation: 1st Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece.
authors.forename: Dimitris
authors.initials: D
authors.lastname: Tousoulis
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D050171:Dyslipidemias / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011322:Primary Prevention / Q000379:methods*; D018570:Risk Assessment; D012307:Risk Factors; D000072657:ST Elevation Myocardial Infarction / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D055502:Secondary Prevention / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Cardiovascular outcomes; STEMI; Statins